IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

Company’s PlaCCine^® technology platform demonstrates better durability and other advantages compared to mRNA vaccines